The US Food and Drug Administration has granted accelerated approval for Regeneron Pharmaceuticals' Otarmeni (lunsotogene parvec-cwha), marking a significant milestone as the first gene therapy specifically designed to treat genetic hearing loss. This approval also makes Otarmeni the second new molecular entity approved under the FDA Commissioner's National Priority Voucher program, highlighting its priority status in medical research and development. The news of this regulatory breakthrough positively impacted Regeneron's stock performance, with shares rising by 2.6% to trade at $766.02 following the announcement. Otarmeni represents a critical advancement in therapeutic options for patients suffering from inherited hearing loss, as it is the inaugural gene therapy authorized for this specific condition. The approval underscores the growing acceptance of gene therapy technologies within the regulatory framework and validates Regeneron's research efforts in advancing curative treatments for previously untreatable genetic disorders. As a novel molecular entity, Otarmeni stands as a distinct therapeutic category, differentiating it from previous drug approvals based on its mechanism of action and target indication. The regulatory approval process involved accelerated review, which typically allows promising therapies to reach patients faster despite potentially being evaluated under less stringent initial safety standards compared to standard full approval pathways. The National Priority Voucher program designation further emphasizes the FDA's interest in incentivizing innovation that addresses unmet medical needs. While the article notes restricted access to additional details such as full interview content or roundups, the core facts confirm the successful completion of regulatory milestones for this transformative medical technology.